What Is Daraxonrasib? Ben Sasse Hails 'Miracle Drug' on Shrinking Tumors
Summary
Ben Sasse, a former U.S. senator diagnosed with advanced pancreatic cancer, says a new drug called daraxonrasib has shrunk his tumors by over 75% in four months. Daraxonrasib is an experimental oral drug targeting RAS proteins, which are involved in many cancers, and it is currently in late-stage clinical trials with promising results.Key Facts
- Ben Sasse was diagnosed with advanced pancreatic cancer in late 2025 and given three to four months to live.
- Daraxonrasib is made by Revolution Medicines and is designed to block RAS proteins that drive many cancers, especially pancreatic cancer.
- Over 90% of pancreatic cancers have tumors driven by mutated RAS proteins.
- Clinical trials show daraxonrasib improves survival rates compared to chemotherapy, with patients living a median of 13.2 months versus 6.7 months.
- The drug is taken orally once daily and has shown a manageable safety profile in trials so far.
- Side effects for Sasse include severe skin irritation and bleeding, which are not commonly reported in the trials.
- The clinical trial involves adults with metastatic pancreatic ductal adenocarcinoma and is ongoing at 60 locations worldwide.
- Pancreatic cancer is the third leading cause of cancer death in the U.S., with about 52,740 expected deaths in 2026.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
